HD-OPM Archive
Topics › Plaque, CAC & CT angiography

Dr Budoff on EVAPORATE: icosapent ethyl with or without PCSK9 inhibitor and plaque in CAD

Gokhan Can · Jul 07, 2025 · ♥ 3 reactions · 11 comments · original Facebook post
Plaque, CAC & CT angiographyPCSK9, ezetimibe & newer drugsFats & oils (saturated fat, seed oils, omega-6, olive oil)
AI summary & key facts

Gokhan shares a short Radcliffe Cardiology video in which Dr Matthew Budoff presents CT data and key EVAPORATE findings on how icosapent ethyl, with or without a PCSK9 inhibitor, affects plaque. No commentary was added; the video was supported by an Amarin educational grant.

(no text — see the shared post below)

Research cited

How does IPE ± PCSK9i inhibitor impact plaque in CAD?

📊 Dr Matthew Budoff shares CT data and key EVAPORATE findings in less than 2 minutes.

This programme is supported by an unrestricted educational grant from Amarin.

#budoff#plaque#pcsk9
← newer: Sarcopenia: no drug should be prescribed; training and proteolder: Germany's Leopoldina urges geroscience-based medicine to tre →